The protective role of coenzyme Q10 in renal injury associated with extracorporeal shockwave lithotripsy: a randomised, placebo‐controlled clinical trial

Abstract

These results are protected by a patent at the Spanish Office of Patents and Trademarks (Reference: P201131992) Objective• To determine the efficacy of coenzyme Q10 (CoQ10) in preventing renal injury in patients with lithiasis undergoing extracorporeal shockwave lithotripsy (ESWL). Patients and Methods• Prospective, randomised, double-blind, placebo-controlled clinical trial of 100 patients with renal lithiasis who were treated with ESWL.• The patients were distributed randomly into two groups receiving either placebo or CoQ10 (200 mg/day), a powerful antioxidant with vasoactive properties, orally administered during the week before ESWL and for 1 week after.• Renal dysfunction markers, vasoactive hormones, oxidative stress, plasma levels of several interleukins and vascular resistance index (VRI) using Doppler ultrasound were evaluated the week before ESWL, 2 h before ESWL and at 2 h, 24 h and 7 days after ESWL. Results• There was a significant increase in glomerular filtration (P = 0.013), as well as a decrease in the albumin/creatinine ratio and the β2-microglobulin level (P = 0.02) after 1 week of treatment in the CoQ10 group. These changes were maintained at the follow-up after ESWL.• The administration of CoQ10 was associated with improvement in vasoactive hormone parameters, VRI and interleukin levels. These improvements were maintained until the end of the follow-up period.• However, the administration of CoQ10 was not associated with significant changes in the oxidative stress parameters. Conclusion• Our results indicate that CoQ10 administration improves renal function and vasoactive and inflammation parameter values, allowing for preconditioning before the tissue insult caused by ESWL.

Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage

“…Coenzyme Q10, a lipophilic cofactor of the mammalian mitochondrial electron transport chain, is not only crucial for mitochondrial energy production (adenosine 5′‐triphosphate [ATP]), but also has emerged as an effective anti‐oxidant. Coenzyme Q10 has shown some clinical benefits in a number of clinical trials. Huynh et al .…”

“…Coenzyme Q10, a lipophilic cofactor of the mammalian mitochondrial electron transport chain, is not only crucial for mitochondrial energy production (adenosine 5 0 -triphosphate [ATP]), but also has emerged as an effective anti-oxidant. Coenzyme Q10 has shown some clinical benefits in a number of clinical trials 67,68 . Huynh et al 69 have treated type 1 diabetic mice at 4 weeks after hyperglycemia that was induced by multiple-low doses of STZ (55 mg/kg/day for 5 days) with coenzyme Q10 or angiotensin-converting-enzyme inhibitor (ACE-I) ramipril for 8 weeks.…”

Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician's point of view

“…The endogenous production of coenzyme Q10 declines after the age of 20, and at the age of 80, only half of endogenous production can be found in the heart [40]. Substantial efforts have been done in numerous studies where supplementation of coenzyme Q10 has been evaluated in different conditions, like multiple sclerosis [41,42] , in Parkinson´s disease [43], in patients with renal injury treated with shockwave lithotripsy [44], in male infertility [45], and in heart disease but with inconsistent results [46][47][48]. Fotino et al reported in a meta-analysis consisting of 13 studies and 395 patients increased cardiac function after coenzyme Q10 supplementation even if the total study sample was small [49].…”

Untitled

“…He noticed an increased glomerular filtration rate in his study along with a reduction in the concentrations of albumin, creatinine, macroglobulin (β2M) in the coenzyme Q 10 treated group. Further, he concluded CoQ 10 actively involved in maintaining renal function, vasoactive hormonal activities and inflammatory parameters after extracorporeal shockwave lithotripsy 24 .…”